Literature DB >> 31066287

PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?

Jacob J Adashek1, Pedro N Aguiar2,3, Pedro Castelo-Branco4,5, Gilberto L Lopes6, Ramon Andrade de Mello7,8,9.   

Abstract

Entities:  

Keywords:  CDK inhibitors; Phase III; hormone-positive HER-2-negative advanced breast cancer; overall survival

Mesh：

Year:  2019        PMID： 31066287     DOI： 10.2217/fon-2019-0044

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  1 in total

1.  Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.

Authors:  Norikazu Masuda; Kenji Tamura; Hiroyuki Yasojima; Akihiko Shimomura; Masataka Sawaki; Min-Jung Lee; Akira Yuno; Jane Trepel; Ryoko Kimura; Yozo Nishimura; Shigehira Saji; Hiroji Iwata
Journal:  BMC Cancer       Date:  2021-11-24       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.